Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.42 |
| ▸ | GPR35 | Q9HC97 | 5/20 | 0.42 |
| ▸ | TDP1 | Q9NUW8 | 3/20 | 0.42 |
| ▸ | MAPT | P10636 | 3/20 | 0.42 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.42 |
| ▸ | MEN1 | O00255 | 2/20 | 0.42 |
| ▸ | HPGD | P15428 | 2/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.42 |
| ▸ | HIF1A | Q16665 | 2/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.42 |
| ▸ | TTR | P02766 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.42 |
| ▸ | RECQL | P46063 | 1/20 | 0.42 |
| ▸ | PMP22 | Q01453 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.41 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL7344459 | 0.82 | MAPK1 (0.39) | ALDH1A1GPR35TDP1MAPTKMT2A | |
| SCHEMBL8903978 | 0.81 | ATM (0.38) | ALDH1A1TDP1MAPTHPGDMAPK1 | |
| SCHEMBL8085829 | 0.81 | ALDH1A1 (0.43) | ALDH1A1GPR35TDP1MAPTKMT2A | |
| SCHEMBL8085548 | 0.81 | ALDH1A1 (0.43) | ALDH1A1MAPTKMT2AMEN1CYP3A4 | |
| SCHEMBL21292987 | 0.77 | VCAM1 (0.47) | ALDH1A1TDP1MAPTKMT2AMEN1 | |
| SCHEMBL157744 | 0.74 | CYP3A4 (0.45) | ALDH1A1GPR35TDP1MAPTKMT2A | |
| SCHEMBL8194088 | 0.73 | SMN1; SMN2 (0.46) | ALDH1A1GPR35TDP1MAPTKMT2A | |
| SCHEMBL30389963 | 0.72 | CYP3A4 (0.43) | ALDH1A1GPR35TDP1MAPTHPGD | |
| SCHEMBL1998053 | 0.72 | CYP3A4 (0.43) | ALDH1A1GPR35TDP1MAPTKMT2A | |
| SCHEMBL1305456 | 0.72 | PTPRC (0.52) | ALDH1A1GPR35TDP1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7892755-B2 | Of nitroquinoxaline-2,3-diones or ellagic acid as binding ligands for G protein coupled receptor 35; antidiabetic agents; anticarcinogenic agents for gastrointestinal cancer; obesity, immunotherapy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-22 | — | — | US | claimed |
| EP-1788390-B1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL (JP) | 2010-04-14 | — | — | EP | claimed |
| US-20080103215-A1 | Screening Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-01 | — | — | US | claimed |
| EP-1788390-A1 | SCREENING METHOD | Takeda Pharmaceutical Company Limited (JP) | 2007-05-23 | — | — | EP | claimed |
| EP-0778023-B1 | Product comprising rapamycin or particular derivatives and an NMDA or AMPA antagonist for use for the treatment of epilepsy or Huntington's Disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or Huntington's Disease. | WYETH CORP (US) | 2003-03-12 | — | — | EP | claimed |
| US-5834465-A | FOR PROTECTING BRAIN AGAINST ACUTE DAMAGE IN STROKE, EPILEPSY, TRAUMA | WASHINGTON UNIVERSITY (US) | 1998-11-10 | — | — | US | claimed |
| EP-0778023-A1 | Neuroprotective agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-06-11 | — | — | EP | claimed |
| US-7892755-B2 | Of nitroquinoxaline-2,3-diones or ellagic acid as binding ligands for G protein coupled receptor 35; antidiabetic agents; anticarcinogenic agents for gastrointestinal cancer; obesity, immunotherapy | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2011-02-22 | — | — | US | disclosed |
| EP-1788390-B1 | SCREENING METHOD | TAKEDA PHARMACEUTICAL (JP) | 2010-04-14 | — | — | EP | disclosed |
| US-20080103215-A1 | Screening Method | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-05-01 | — | — | US | disclosed |
| EP-1788390-A1 | SCREENING METHOD | Takeda Pharmaceutical Company Limited (JP) | 2007-05-23 | — | — | EP | disclosed |
| US-6974814-B2 | Neuropharmacological treatment of sleep-related breathing disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2005-12-13 | — | — | US | disclosed |
| US-20030236228-A1 | Neuropharmacological treatment of sleep-related breathing disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2003-12-25 | — | — | US | disclosed |
| US-6555564-B1 | Neuropharmacological treatments of sleep-related breathing disorders | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS | 2003-04-29 | — | — | US | disclosed |
| EP-0778023-B1 | Product comprising rapamycin or particular derivatives and an NMDA or AMPA antagonist for use for the treatment of epilepsy or Huntington's Disease, and the use of rapamycin or particular derivatives for the manufacture of a medicament for the treatment of epilepsy or Huntington's Disease. | WYETH CORP (US) | 2003-03-12 | — | — | EP | disclosed |
| WO-2000051590-A2 | NEUROPHARMACOLOGICAL TREATMENT OF SLEEP-RELATED BREATHING DISORDERS | THE BOARD OF TRUSTEES OF THE UNIVERSITY OF ILLINOIS (US) | 2000-09-08 | — | — | WO | disclosed |
| EP-0778023-A1 | Neuroprotective agents | AMERICAN HOME PRODUCTS CORPORATION (US) | 1997-06-11 | — | — | EP | disclosed |